Navigation Links
Man Without Human Heart Hikes More Than 400 Miles
Date:8/1/2012

TUCSON, Ariz., Aug. 1, 2012 /PRNewswire/ -- Hiking up to six miles every day isn't for the faint of heart. Luckily for Chris Marshall, he doesn't have one. Marshall, the first SynCardia temporary Total Artificial Heart patient in the Pacific Northwest to leave the hospital using the Freedom® portable driver, has logged more than 400 miles of hiking since being discharged from University of Washington Medical Center on March 29.

(Photo: http://photos.prnewswire.com/prnh/20120801/LA50039)

"I've walked just about 437 miles since I was discharged," said Marshall. "I feel so much better with the Total Artificial Heart than I was feeling before. My color is greatly improved, my vitality is going up. With the Total Artificial Heart and the Freedom driver, I really get to go out and live life."

In 1999, Marshall was diagnosed with cardiomyopathy, a disease that destroys the heart muscle over time, and ventricular tachycardia, an irregular, fast heartbeat. Although his implanted defibrillator shocked his heart 30 times over a 12-year span, Marshall never let his heart condition slow him down.

"I actually did very well with a low heart ejection fraction for many years," said Marshall. "My doctors did a really good job of managing me medically. I was doing a lot of hiking - 3 to 5 miles a day - with an ejection fraction around 20 percent. A healthy ejection fraction is around 50 to 70 percent. It was only this past fall that I started getting shortness of breath on level ground, which had never happened before."

On Jan. 23, Marshall and his wife Kathy traveled from their home in Wasilla, Alaska, to Seattle for what was supposed to be a one-day heart evaluation. However, doctors discovered his heart was functioning at less than 10 percent, and didn't think he would survive the flight home.

"I was walking 20 laps a day in the hospital hallways at a very fast clip," said Marshall. "So when my surgeon told me that he wanted to replace my heart with the Total Artificial Heart, it seemed kind of drastic."

Marshall's surgeon, Dr. Nahush Mokadam, wanted to do the surgery on Feb. 6. As the date approached, it was up to Marshall to decide whether to proceed with implanting the SynCardia Total Artificial Heart.

"On Feb. 5, I ended up having ventricular tachycardia after walking my sixth lap around the hospital floor," said Marshall. "I lost consciousness and when I woke up, I was lying on the floor with the IV pole next to me. After that, everyone agreed that the Total Artificial Heart wasn't a bad idea.

"I told them yes, let's go ahead with it."

Marshall was implanted with the Total Artificial Heart during a six-hour procedure on Feb. 6. Seven weeks later, on March 21, he was discharged from University of Washington Medical Center using the Freedom portable driver to power his Total Artificial Heart. Since his discharge, Marshall has enjoyed hiking in the Seattle area with his wife Kathy and his golden retriever Gracie.

Weighing 13.5 pounds, the Freedom portable driver is the world's first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

Watch slideshow narrated by Dr. Nahush Mokadam
Read feature story in UW Medicine's Consult magazine
View patient story told in Chris Marshall's own words

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

Sign-up to receive the latest news updates from SynCardia
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Wins Two Gold Stevies® at 2012 American Business Awards

On June 18, 2012, SynCardia was honored with two Gold Stevie® Awards at the 10th Annual American Business Awards. SynCardia won "Company of the Year – Health Products and Services" and "Most Innovative Company of the Year – up to 100 Employees." See the full list of SynCardia Awards & Recognition, which includes accolades from Forbes, Fast Company and more.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
2. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
3. Robai Offers Cyton Gamma Humanoid Robot Arm
4. Hologic Human Papillomavirus (HPV) High-Risk Test Approved for Use in The Netherlands Population Cervical Screening Programme
5. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
6. The Healing Power of Human Milk
7. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
8. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
9. ReproCELL Launches Alzheimers Disease Model Based on iPS-derived Human Neuronal Cells
10. Global Human Vaccines Industry
11. SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... new report published by Allied Market Research titled, ... Opportunities and Forecasts, 2014-2020", estimates the world synthetic ... Nucleotide synthesis and sequencing technology segment would continue ... and software tools segment, collectively, held around half ...
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  Despite ... has been slower than other industries to embrace Big ... come with utilization. On the medical side, organizations have ... improve everything from clinical trials to adherence. ... research from benchmarking firm Best Practices, LLC, Big Data ...
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical ... aesthetic device company, announced today that William ... North America, is scheduled to participate in the ... Conference on February 11, 2016 in ... allow institutional investors to meet with the Mr. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... be speaking on how healthcare companies can use newly released government data on ... of a population and intervene and capture the value they create to succeed ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... only four states in the U.S. require dental technicians to be certified or ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart ... employers and organizations with the tools and information to lower the costs, and ... cut the cost of providing employee healthcare benefits by as much as 22%:, ...
(Date:2/6/2016)... ... , ... US Sports Camps is proud to sponsor the Bay Area Disc ... non-profit leaders, ultimate organizations, and coaches from around the US. The theme for this ... Director of Youth and Education, describes this year YUCC as “an important conversation we ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
Breaking Medicine News(10 mins):